4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation (Dutch-AMR)

Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation (Dutch-AMR)

Study Description
Brief Summary:

Rationale:

Severe asymptomatic organic Mitral Valve (MV) regurgitation with preserved left ventricular (LV) function is a challenging clinical entity as data on the recommended treatment strategy for these patients are scarce and conflicting, which is reflected in current guidelines. European guidelines advocate a more conservative strategy i.e. watchful waiting, with yearly echocardiography, whilst American guidelines are more in favour of early surgery to reconstruct the MV, i.e. MV repair (in contrast to MV replacement) in order to prevent future LV dysfunction and complaints.

A number of non-randomised trials show a favourable outcome of early surgery: in the study of Enriquez-Sarano et al. for instance, the early surgery strategy has shown to be associated with improved long-term survival, decreased cardiac mortality, and decreased morbidity compared with the conservative management [1]. On the other hand, non-randomised trials describe also that a conservative strategy (i.e. watchful waiting) can be safely accomplished. If facilitated surgery is performed in this population (50% at 10 years follow-up according to Rosenhek et al [2]), it has proven to be eventually associated with good perioperative and postoperative outcome when careful follow-up is being carried out [2].

Objective:

To compare early MV repair versus watchful waiting in asymptomatic patients with severe organic mitral valve regurgitation and preserved left ventricular function.

Study design:

Multicenter, registry trial.

Study population:

250 Asymptomatic patients (18-75 years old) with severe organic MV regurgitation and preserved left ventricular function. The current European Society of Cardiology (ESC) guidelines on Valvular Heart Disease will be applied [3]. These guidelines are also used in the Netherlands. Accordingly, patients with an indication for MV surgery will not be included.

Intervention:

Intervention will be early MV repair compared to a watchful waiting strategy.


Condition or disease Intervention/treatment
Mitral Regurgitation Procedure: Mitral valve repair

Study Design
Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Dutch-AMR Study: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Organic Mitral Regurgitation and Preserved Ejection Fraction: a Multicenter Registry Trial
Study Start Date : October 2016
Estimated Primary Completion Date : October 2026
Estimated Study Completion Date : October 2031
Arms and Interventions
Group/Cohort Intervention/treatment
Aymptomatic patients with severe mitral regurgitation
Watchful waiting Early Surgery
Procedure: Mitral valve repair
Minimally invasive repair of severe organic mitral regurgiation

Outcome Measures
Primary Outcome Measures :
  1. Time to event: cardiovascular mortality, congestive heart failure, hospitalization, class I or class IIa indication for MV surgery [ Time Frame: 5 years ]

Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Asymptomatic patients with severe organic mitral regurgitation and preserved ejection fraction.
Criteria

Inclusion Criteria:

  • 18-75 years.
  • Asymptomatic patients. "Asymptomatic" is defined as absence of subjective limitations of exercise capacity or complaints expressed by the patient and confirmed by the treating cardiologist.
  • Severe organic mitral valve regurgitation. "Severe organic mitral valve regurgitation" is defined as non-ischemic mitral valve regurgitation with an organic cause (intrinsic valve lesion) as determined by echocardiographic core-lab reading based on the criteria for definition of severe MR as issued by the ESC guidelines [4]. For practical reasons, referring cardiologists can use an ESC guidelines based index that was validated in the investigator's core-lab (Jansen et al, Practical echocardiographic semi-quantitative scoring system to determine severity of mitral regurgitation. Abstract presentation at ESC EUROECHO Congress 2011 and annual spring congress 2012 Netherlands Society of Cardiology).
  • Preserved left ventricular function, "Preserved left ventricular function" is defined as left ventricular ejection fraction >60% and left ventricular end-systolic dimension <45 mm (no indexed value, measured by echocardiography).
  • The likelihood of MV repair should be more than 90% determined by the local heart team with a cardiologist and cardiothoracic surgeon.

Exclusion Criteria:

  • Pulmonary hypertension (>50 mmHg at rest).
  • Atrial fibrillation, either on 12-lead ECG or holter-monitoring.
  • Physical inability as determined by the heart team to undergo surgery.
  • Other life-threatening morbidity.
  • Higher expected surgical risks in advance, according to the dedicated heart team.
  • Patients with moderate to severe kidney disease (estimated glomerular filtration rate (eGFR) less than 30 mL/min).
  • Flail leaflet together with a left ventricular end systolic diameter (LVESD) ≥40 mm (no indexed value)
Contacts and Locations

Locations
Layout table for location information
Netherlands
Amsterdam Medical Center (AMC) Recruiting
Amsterdam, Netherlands
Contact: Matthijs Boekholdt       s.m.boekholdt@amsterdamumc.nl   
Sub-Investigator: Jolanda Kluin         
Principal Investigator: Matthijs Boekholdt         
Sub-Investigator: Rene van den Brink         
Amphia Breda Recruiting
Breda, Netherlands
Contact: Jeroen Schaap       jschaap@amphia.nl   
Principal Investigator: Jeroen Schaap, MD         
Medisch Spectrum Twente (MST) Recruiting
Enschede, Netherlands
Contact: Lodewijk Wagenaar       L.Wagenaar@mst.nl   
Principal Investigator: Lodewijk Wagenaar         
Leiden University Medical Center (LUMC) Active, not recruiting
Leiden, Netherlands
Maastricht UMC Recruiting
Maastricht, Netherlands
Contact: Bas Streukens       bas.streukens@mumc.nl   
University Medical Center Utrecht (UMC Utrecht) Recruiting
Utrecht, Netherlands, 3584 CX
Contact: Steven AJ Chamuleau, MD, PhD    0031 88 75 59801    S.A.J.Chamuleau@umcutrecht.nl   
Principal Investigator: Steven AJ Chamuleau, MD, PhD         
Sub-Investigator: Einar A Hart, MD         
Sub-Investigator: Maarten Jan M Cramer, MD, PhD         
Sponsors and Collaborators
UMC Utrecht
Netherlands Heart Institute
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Amphia Hospital
Maastricht University Medical Center
Medisch Spectrum Twente
Leiden University Medical Center
Tracking Information
First Submitted Date November 28, 2016
First Posted Date June 5, 2019
Last Update Posted Date June 6, 2019
Study Start Date October 2016
Estimated Primary Completion Date October 2026   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: June 4, 2019)
Time to event: cardiovascular mortality, congestive heart failure, hospitalization, class I or class IIa indication for MV surgery [ Time Frame: 5 years ]
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation
Official Title Dutch-AMR Study: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Organic Mitral Regurgitation and Preserved Ejection Fraction: a Multicenter Registry Trial
Brief Summary

Rationale:

Severe asymptomatic organic Mitral Valve (MV) regurgitation with preserved left ventricular (LV) function is a challenging clinical entity as data on the recommended treatment strategy for these patients are scarce and conflicting, which is reflected in current guidelines. European guidelines advocate a more conservative strategy i.e. watchful waiting, with yearly echocardiography, whilst American guidelines are more in favour of early surgery to reconstruct the MV, i.e. MV repair (in contrast to MV replacement) in order to prevent future LV dysfunction and complaints.

A number of non-randomised trials show a favourable outcome of early surgery: in the study of Enriquez-Sarano et al. for instance, the early surgery strategy has shown to be associated with improved long-term survival, decreased cardiac mortality, and decreased morbidity compared with the conservative management [1]. On the other hand, non-randomised trials describe also that a conservative strategy (i.e. watchful waiting) can be safely accomplished. If facilitated surgery is performed in this population (50% at 10 years follow-up according to Rosenhek et al [2]), it has proven to be eventually associated with good perioperative and postoperative outcome when careful follow-up is being carried out [2].

Objective:

To compare early MV repair versus watchful waiting in asymptomatic patients with severe organic mitral valve regurgitation and preserved left ventricular function.

Study design:

Multicenter, registry trial.

Study population:

250 Asymptomatic patients (18-75 years old) with severe organic MV regurgitation and preserved left ventricular function. The current European Society of Cardiology (ESC) guidelines on Valvular Heart Disease will be applied [3]. These guidelines are also used in the Netherlands. Accordingly, patients with an indication for MV surgery will not be included.

Intervention:

Intervention will be early MV repair compared to a watchful waiting strategy.

Detailed Description Not Provided
Study Type Observational [Patient Registry]
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration 5 Years
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Asymptomatic patients with severe organic mitral regurgitation and preserved ejection fraction.
Condition Mitral Regurgitation
Intervention Procedure: Mitral valve repair
Minimally invasive repair of severe organic mitral regurgiation
Study Groups/Cohorts Aymptomatic patients with severe mitral regurgitation
Watchful waiting Early Surgery
Intervention: Procedure: Mitral valve repair
Publications *
  • Ling LH, Enriquez-Sarano M, Seward JB, Orszulak TA, Schaff HV, Bailey KR, Tajik AJ, Frye RL. Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study. Circulation. 1997 Sep 16;96(6):1819-25.
  • Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. 2006 May 9;113(18):2238-44. Epub 2006 May 1.
  • Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007 Jan;28(2):230-68. Epub 2007 Jan 26.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: June 4, 2019)
500
Original Estimated Enrollment Same as current
Estimated Study Completion Date October 2031
Estimated Primary Completion Date October 2026   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • 18-75 years.
  • Asymptomatic patients. "Asymptomatic" is defined as absence of subjective limitations of exercise capacity or complaints expressed by the patient and confirmed by the treating cardiologist.
  • Severe organic mitral valve regurgitation. "Severe organic mitral valve regurgitation" is defined as non-ischemic mitral valve regurgitation with an organic cause (intrinsic valve lesion) as determined by echocardiographic core-lab reading based on the criteria for definition of severe MR as issued by the ESC guidelines [4]. For practical reasons, referring cardiologists can use an ESC guidelines based index that was validated in the investigator's core-lab (Jansen et al, Practical echocardiographic semi-quantitative scoring system to determine severity of mitral regurgitation. Abstract presentation at ESC EUROECHO Congress 2011 and annual spring congress 2012 Netherlands Society of Cardiology).
  • Preserved left ventricular function, "Preserved left ventricular function" is defined as left ventricular ejection fraction >60% and left ventricular end-systolic dimension <45 mm (no indexed value, measured by echocardiography).
  • The likelihood of MV repair should be more than 90% determined by the local heart team with a cardiologist and cardiothoracic surgeon.

Exclusion Criteria:

  • Pulmonary hypertension (>50 mmHg at rest).
  • Atrial fibrillation, either on 12-lead ECG or holter-monitoring.
  • Physical inability as determined by the heart team to undergo surgery.
  • Other life-threatening morbidity.
  • Higher expected surgical risks in advance, according to the dedicated heart team.
  • Patients with moderate to severe kidney disease (estimated glomerular filtration rate (eGFR) less than 30 mL/min).
  • Flail leaflet together with a left ventricular end systolic diameter (LVESD) ≥40 mm (no indexed value)
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Listed Location Countries Netherlands
Removed Location Countries  
 
Administrative Information
NCT Number NCT03975998
Other Study ID Numbers 16/743
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party S.A.J. Chamuleau, UMC Utrecht
Study Sponsor UMC Utrecht
Collaborators
  • Netherlands Heart Institute
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Amphia Hospital
  • Maastricht University Medical Center
  • Medisch Spectrum Twente
  • Leiden University Medical Center
Investigators Not Provided
PRS Account UMC Utrecht
Verification Date June 2019